期刊文献+

大肠癌VEGFR-3与Prox1的相关性研究 被引量:3

The relationship between the expression of VEGFR-3 and Prox1 in colorectal cancer
下载PDF
导出
摘要 目的探讨VEGFR-3和Prox1在大肠癌组织、正常黏膜组织和淋巴结中的表达及其相互关系。方法采用实时定量RT-PCR检测63份直肠癌远端肠壁组织,156枚系膜淋巴结,配对肿瘤组织和邻近正常黏膜组织各13份的VEGFR-3,Prox1的表达。结果VEGFR-3和Prox1的mRNA含量中位数在肿瘤远端肠壁组织分别为22.08和544.97,两者有明显相关性(r=0.716,P=0.000 1)。在淋巴结分别为33.81和439.16,两者有明显相关性(r=0.618,P=0.000 1)。在肿瘤组织分别为0.65和5877,两者没有相关性(r=-0.280,P=0.353)。结论VEGFR-3与Prox1在正常肠壁组织和系膜淋巴结的新生淋巴管形成中可能有协同作用,但在肿瘤组织不存在协同关系。 Objective To investigate the expression and relationship between VEGFR-3 and Proxl in the tissues of tumor, normal mucosa and lymph nodes from the surgieal resection specimens of colorectal cancer. Methods Sixty- three normal intestinal tissues distal to rectal tumor, 156 mesentery lymph nodes and 13 matched pairs of tumor and adjacent nontumorous mucesa samples from patients with colorectal cancer were measured for VEGFR- 3 and Proxl expression using quantitative realtime RT-PCR. Results The median of VEGFR- 3 and Proxl mBNA content in intestinal tissues distal to rectal tumor was 22.08 and 544.97 respeetivdy, between which a significant correlation was found (r =0.716, P=0.000 1). It was 33.81 and 439.16 in mesentery lymph nodes respeetivdy, and they were significantly correlated to each other ( r = 0.618, P = 0.000 1). There was no significant correhtion (r= -0.280, P=0.353) between the VEGFR- 3 expression (median 0.65) and Proxl expression ( median 0.65) in tumor tissues. Conclusions VEGFR - 3 and Proxl may synergieally involve in the lymphangiogenesis in normal intestinal tissue and mesentery lymph nodes, but they lack of correlation in tumor tissues.
出处 《广东医学》 CAS CSCD 北大核心 2005年第11期1488-1490,共3页 Guangdong Medical Journal
基金 广东省医学科学技术研究基金资助项目(编号:B2005050)
关键词 VEGFR-3 Proxl 大肠癌组织 膜淋巴结 肿瘤组织 肠壁组织 黏膜组织 协同作用 RNA含量 淋巴管形成 实时定量 PROM 直肠癌 中位数 远端 Coloreetal cancer Vascular endothelial growth factor receptor 3 Prox- 1 game Lymphangiogenesis
  • 相关文献

参考文献8

  • 1Folkman J, Kaipainen A. Genes tell lymphatics to sprout or not. Nature Immunology, 2004, 5(1): 11.
  • 2Krishnan J, Kirkin V, Steffen A, et al. Differential in vivo and in vitro expression of vascular endothelial growth factor (VEGF) - C and VEGFD in tumors and its relationship to lymphatic metastasis in immunocompetent rats. Cancer Res, 2003, 63(3): 713.
  • 3Bieche I, Nogues C, Paradis V, et al. Quantitation of hTERT gene expression in sporadic breast tumors with a real - time reverse transcriptionpolymerase chain reaction assay. Clin Cancer Res, 2000, 6(2): 452.
  • 4Reis- Filho JS, Schmitt FC. Lymphangiogenesis in tumors: What do we know? Microscopy Res Tech, 2003, 60(2): 171.
  • 5Partanen TA, Alitalo K, Miettinen M. Lack of lymphatic vascular specificity of vascular endothelial growth factor receptor 3 in 185 vascular tumors. Cancer, 1999, 86(11): 2406.
  • 6Wigle JT, Oliver G. Prox1 function is required for the development of the murine lymphatic system. Cell, 1999, 98(6): 769.
  • 7Tille JC, Nisato R, Pepper MS. Lymphangiogenesis and tumour metastasis. Novartis Found Symp, 2004, 256:112.
  • 8McCarter MD, Claske JH, Harken AH. Lymphangiogenesis is pivotal to the trials of a successful cancer metastasis. Surgery, 2004, 135(2): 121.

同被引文献73

引证文献3

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部